After many years of research, small diameter, synthetic vascular grafts still lack the necessary biologic integration to perform ideally in clinical settings. Endothelialization of vascular grafts has the potential to improve synthetic graft function, and endothelial outgrowth cells (EOCs) are a promising autologous cell source. Yet no work has established the link between endothelial cell functions and outcomes of implanted endothelialized grafts. This work utilized steady flow, oscillatory flow, and tumor necrosis factor stimulation to alter EOC phenotype and enable the formulation of a model to predict endothelialized graft performance. To accomplish this, EOC in vitro expression of coagulation and inflammatory markers was quantified. In parallel, in non-human primate (baboon) models, the platelet and fibrinogen accumulation on endothelialized grafts were quantified in an ex vivo shunt, or the tissue ingrowth on implanted grafts were characterized after 1mth. Oscillatory flow stimulation of EOCs increased in vitro coagulation markers and ex vivo platelet accumulation. Steady flow preconditioning did not affect platelet accumulation or intimal hyperplasia relative to static samples. To determine whether in vitro markers predict implant performance, a linear regression model of the in vitro data was fit to platelet accumulation data-correlating the markers with the thromboprotective performance of the EOCs. The model was tested against implant intimal hyperplasia data and found to correlate strongly with the parallel in vitro analyses. This research defines the effects of flow preconditioning on EOC regulation of coagulation in clinical vascular grafts through parallel in vitro, ex vivo, and in vivo analyses, and contributes to the translatability of in vitro tests to in vivo clinical graft performance.
Introduction
Vascular grafts are an essential technology for treating cardiovascular disease, the dominant cause of death in our society. An estimated 416,000 bypass grafts procedures occurred in 2009 in the United States alone [1] . Bypass grafts represent an important intervention to treat vessel blockage, with autologous saphenous vein or mammary artery tissues remaining the standard treatment for the past 30 years. Artificial materials are used when native tissues are unavailable; while these materials have the mechanical properties to withstand suturing and arterial blood forces, their compliance mismatch encourages intimal hyperplasia and leads to graft failure. Many of these materials also lack the biologic capacity, predominantly due to the lack of endothelial-dependent regulatory functions, to integrate with the surrounding vessels leading to thrombosis. At small diameters (,5 mm), tissue thickening leads to a decrease in the graft lumen resulting in occlusive failure of the graft. As reviewed elsewhere, various biologic materials are being used or developed for vascular grafts, but current clinical products still have considerable limitations in mechanical integrity, patient wait time, immune rejection, and ultimately patency [2] .
Given the limited ability of an artificial graft to fully endothelialize in humans [3] , a tissue-engineered graft or endothelialized biomaterial may be a more desirable implant when a native graft is unavailable. Endothelial cells tightly control vascular homeostasis. As reviewed previously, endothelial cells produce a multitude of transmembrane glycoproteins and released factors which regulate coagulation, thrombin generation, and platelet activity [4] [5] [6] . Of particular interest to this work are activated factor X (FXa), which converts prothrombin to thrombin, and activated protein C (APC), which leads to a downregulation of thrombin. The activation of APC is enhanced by endothelial transmembrane glycoproteins, thrombomodulin (TM) and endothelial protein C receptor (EPCR). Factor Xa results from the complex of transmembrane tissue factor (TF) with factor VIIa, while endothelial cell release of tissue factor pathway inhibitor (TFPI) inhibits both FXa and the TF-factor VIIa complex. Endothelial cells regulate platelet activation through the production of the enzyme endothelial nitric oxide synthase (eNOS) resulting in nitric oxide release and the expression of transmembrane CD39 [5] . In addition to thrombosis and hemostasis, endothelial cells are central regulators of inflammation [7, 8] . Intercellular adhesion molecule-1 (ICAM), vascular cell adhesion molecule-1 (VCAM), and platelet endothelial cell adhesion molecule (PECAM) are endothelial transmembrane proteins that facilitate leukocyte adhesion and migration in inflammation. Combined, these endothelial functions cooperatively regulate the processes of hemostasis, inflammation, and intimal hyperplasia. Endothelialization of vascular grafts has been demonstrated to improve vascular graft patency by properly regulating these processes and facilitating integration with the surrounding tissue [9] [10] [11] [12] . Biochemical or mechanical, particularly fluid shear stress, stimulation can be used to alter and improve endothelial cell phenotype. Steady, laminar fluid flow with physiological shear stress leads to endothelial cell elongation and alignment in the direction of flow, decreased cell proliferation, decreased monocyte adhesion, and downregulation of endothelial regulated immunogenicity. Alternatively, low or disturbed flow leads to a lack of cell alignment and an increase in immunogenicity [6] . The phenotype of the elongated endothelial cell improves thromboprotective function, suggesting that preconditioning an endothelialized graft may result in superior in vivo performance.
To obtain autologous endothelial cells for graft endothelialization would require an invasive harvest, while implantation of endothelial cells from allogenic or xenogenic sources would require continuous immune suppression. Given the limited supply of attainable mature vascular endothelial cells, endothelial outgrowth cells (EOCs), which are obtained from a simple blood draw and expand rapidly in culture, are an attractive autologous cell source for an engineered endothelium. This descendent of endothelial progenitor cells has seen widespread use in the past decade. Recent work has begun to characterize EOCs under various shear conditions and found similar results to the well-established shear responses seen with mature endothelial cells [13] [14] [15] [16] . EOCs exhibited the most thromboprotective and immunoprotective phenotype after stimulation with steady fluid shear stress and the most thromboprone phenotype after stimulation with oscillatory shear stress [14] . EOCs were also responsive to tumor necrosis factor (TNF), a potent proinflammatory cytokine [13, 15, 17] . Stimulation with these mechanical or biochemical stimuli should elicit a large range of EOC phenotypes.
A critical limitation for all research on vascular graft development is the lack of testing modalities that translate into improved clinical function. In vivo testing in relevant animal models will be an essential final step in determining the performance of any graft, but it is neither cost-effective nor feasible for initial studies. Therefore, many researchers test a panel of coagulation or inflammation markers on their cell source and/or biomaterial of choice. As reviewed previously [18] , many studies have attempted to mimic in vivo graft performance by examining the response of a single blood component (e.g., platelets or leukocytes), but these simplified models are unlikely to accurately represent the in vivo performance of the graft. Even the majority of implant models lack the strength to generate clinical translatability. Small animal models, which often employ a short (1-2cm length) end-to-end graft, spontaneously endothelialize and do not model human vascular graft responses [19] .
To address these limitations we used two, well-established baboon models: an ex vivo shunt model and an in vivo end-to-side graft. The shunt model uses whole blood at physiologic arterial flow conditions to recapitulate coagulation factor transport dynamics. Furthermore, this model characterizes vascular graft thrombogenicity without anticoagulants to more accurately reflect how grafts will perform in patients who will not be given anticoagulants long-term [20] [21] [22] [23] [24] [25] . The baboon aorto-iliac implant model of an end-to-side 4mm diameter vascular graft is designed to most closely relate to the clinical use of vascular grafts in humans, thereby maximizing the translatability of this research [19, 26] . This model does not spontaneously endothelialize, but rather shows an ingrowth of smooth muscle cells and endothelial cells at a rate of 0.2 mm/day [26] . For both these models, we examined EOCs on a clinically-relevant graft material, expanded polytetrafluoroethylene (ePTFE). While this material did not address the compliance mismatch plaguing artificial vascular grafts, the grafts represent the current gold-standard artificial material. By performing in vitro analyses of thrombosis and inflammation in parallel with ex vivo or in vivo responses in these non-human primate models, we identified the in vitro metrics that best correlate to platelet accumulation and performance in the body. Using both biochemical and mechanical methods to alter EOC phenotype we aimed to generate correlations with broad applicability. Specifically, we tested the EOCs in vascular grafts under static culture conditions, steady and oscillatory fluid shear stress preconditioning, and TNF stimulation. These stimuli generated a large range of phenotypic responses which facilitated the development of a linear regression model correlating in vitro EOC responses to platelet or tissue ingrowth in vascular grafts. We hypothesized that 1) steady fluid shear stress would lead to a more anticoagulant and anti-inflammatory EOC phenotype in vitro, reduced platelet accumulation ex vivo, and reduced intimal hyperplasia in vivo, and 2) in vitro metrics of the EOC functions would correlate with ex vivo platelet accumulation. Identification of these metrics now provides an essential starting point for all vascular graft research to more rapidly improve clinical vascular grafts. This multifaceted research determined not only the performance of this clinicallyrelevant, cell-based therapy in vivo, but also the ability to predict in vivo and ex vivo responses based on in vitro analyses.
Materials and Methods

Experimental Design
These studies were designed to examine EOC coagulation and inflammatory markers in vitro, platelet and fibrinogen accumulation ex vivo, and endothelialized graft performance in vivo on EOC-seeded ePTFE grafts. Oscillatory or steady fluid flow preconditioning, as well as TNF treatment, was performed on EOC-seeded grafts to elicit a range of EOC phenotypes. In vitro analyses were performed on EOC-seeded grafts prepared and treated in parallel with samples used for the ex vivo shunt studies and the in vivo implant studies to determine correlations between in vitro analyses and ex vivo or in vivo performance. Samples were tested in vitro for cell coverage using fluorescent microscopy and DNA quantity, for FXa and APC production using biochemical assays, and for gene expression using qRT-PCR. In parallel, a baboon, femoral, arteriovenous shunt model, which utilizes whole blood lacking anticoagulation with radiolabeled platelets and fibrinogen, was used to quantify platelet and fibrin accumulation on the cellseeded grafts. Alternatively, intimal hyperplasia was quantified on end-to-side aorto-iliac bypasses using a blind analysis on cell-seeded grafts implanted contralaterally to untreated controls in a baboon implant. These parallel analyses of preconditioning EOC-seeded vascular grafts were performed to determine correlations resulting from in vitro metrics of EOC phenotype. Raw data can be found in the supporting files (S1 File).
EOC isolation, culture, and flow pretreatment
Late-outgrowth, baboon EOCs were derived from the mononuclear cells of peripheral blood as described previously [27] . Cell phenotype was confirmed after passage 1 by selecting for PECAM positive cells using Dynabeads (Invitrogen) according to the manufacturer's protocol. EOCs were maintained in endothelial growth media-2 (Lonza) with 10% fetal bovine serum on collagen-coated tissue culture plastic and used at passage 5 in these studies. Graft lengths of 50 or 70 mm of ePTFE with a 4 mm internal diameter (Gore-Tex, W.L. Gore and Associates, Inc.) were connected to silicone tubing, maintaining a smooth lumen. Grafts were then coated with 4 mg/mL bovine collagen I (MP Biomedicals), and seeded with EOCs in a custom biochamber, as described previously [28] . After 24hrs, the media was switched to a higher viscosity flow media to mimic blood viscosity: 15% solution of 100 g/L dextrose and 320 g/L dextran from Leuconostoc mesentreroides (Sigma, molecular weight548,000-90,000) in endothelial basal media (Lonza) with 5% fetal bovine serum, 1% Penicillin-Streptomycin, 1% Lglutamine, and 0.1% epidermal growth factor. Samples were either stimulated with 10 dyn/cm 2 steady shear flow, 0¡10 dyn/cm 2 oscillatory shear flow at 1 Hz, or kept as static cultures for an additional 24hrs.
In vitro assessments
Grafts for in vitro analyses were prepared in parallel with grafts used for in vivo or ex vivo studies. All analyses were performed on all in vitro samples.
Fluorescent staining
EOC-seeded graft segments (about 10 mm in length) were stained for F-actin with AlexaFluor 568 phalloidin and nuclear co-stained with DAPI, as described previously [28] . For PECAM staining, graft sections were incubated with mouse anti-human PECAM (Dako) overnight at 4˚C, washed in PBS with 0.1% BSA, and stained with AlexaFluor 568-tagged goat anti-mouse IgG (Invitrogen). Stained sections were mounted with ProLong Gold antifade reagent (Invitrogen) and imaged using an Olympus FV1000 confocal microscope and Fluoview software.
Total DNA
The DNA content of EOC-seeded graft segments was measured with the PicoGreen dsDNA assay according to the manufacturer's protocol (Invitrogen) and normalized by graft surface area after measurements with digital calipers.
qRT-PCR
Cells were lysed from a 25-35 mm long section of ePTFE, and RNA was isolated from the lysate using an RNeasy mini isolation kit (Qiagen). Samples were reverse transcribed with SuperScript III Reverse Transcriptase (Invitrogen) according to the manufacturers' protocols. Gene expression was quantified using Platinum SYBR Green and ROX reference dye (Invitrogen) with in-house designed primers at 250 nM concentration (S1 Table) . All in vitro samples were tested for a panel of coagulation and inflammation genes, specifically, CD39, EPCR, TM, eNOS, ICAM, VCAM, PECAM, TF, and TFPI. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as a housekeeping gene and ddct values were determined by comparing treated samples to static controls. Data were transformed by subtracting 1 from any positive 2
-ddct values and taking the negative inverse of any negative 2
-ddct values and adding 1. This resulted in a continuous, linear data set and is referred to as fold change, where the static values are 0. Positive values show an increase from paired static samples, while negative values indicate a decrease from the static control.
Functional assays
EOC-seeded graft segments approximately 3 mm in length were incubated with 5 nM thrombin (Haematologic Technologies) and 100 nM Protein C (Haematologic Technologies) for 60 min at 37˚C to generate APC. Refludan (Berlex) or hirudin was used to inactivate the thrombin, and a chromogenic substrate (1 mM S-2366, Chromogenix) was used to quantify APC generation by comparing it to an APC standard (Haematologic Technologies). Graft segments for FXa quantification approximately 3 mm in length were incubated with 20 nM factor VIIa (Enzyme Research Laboratories) and 200 nM factor X (Enzyme Research Laboratories) for 60 min at 37˚C. Cold EDTA (5 nM) was used to stop the reaction, and 0.67 mM Spectrozyme FXa (American Diagnostica) was used to measure FXa generation compared to a FXa standard. Absorbance at 405 nm was measured every 20 s for 20 min and the maximum slope over 10 points used to quantify APC or FXa. Data were normalized by the graft segment area.
Animal care and ethics
Male baboons (Papio anubis) were cared for and housed at the Oregon National Primate Research Center (ONPRC) at Oregon Health & Science University. All the experiments described here were reviewed and approved (approval numbers indoor or indoor/outdoor facilities. Nonhuman primates are routinely fed commercially prepared primate feed milled within the past 90days. This feed is supplemented daily with fruit and special diets prepared in the ONPRC diet kitchen. Fresh, potable water is provided by the municipal water district via automatic water systems. The nonhuman primates are provided with daily enrichment including (1) toys (in cage at all times and rotated every 2 weeks) and (2) devices (foraging manipulanda) on the outside of the cage, also changed every 2 weeks. The devices are filled with trail mix, grain, and/or produce at least 3 days per week. The nonhuman primates receive produce on days the devices are not filled, (3) TV/radio on a weekly rotation schedule, (4) pair housing/grooming contact (as much as possible), (5) positive reinforcement training, and (6) cognitive enrichment (computer tablets, such as Kindles). Steps are taken to ameliorate suffering according to the Weatherall Report ''The use of non-human primates in research.'' During experimentation, the animals are monitored for behavior, appetite, and stool quantity. The technician reports any abnormalities on a daily observation sheet, which is checked daily by a member of the clinical services unit and the behavioral services unit. Any notations by the technician about abnormalities with the animal are addressed by both the clinical services unit and the behavioral services unit.
For all surgical procedures, animals were anesthetized with 1-3% isofluorane delivered at 1-2 L/min in 100% oxygen after induction by ketamine (10-20 mg/ kg intramuscularly) and Telazol (3-5 mg/kg intramuscularly). During the procedure the DAR staff monitored pulse rate, body temperature, blood pressure, ECG, oxygen saturation, and exhaled CO 2 . Adequacy of anesthesia was additionally assessed by observable spontaneous movements, and physical, circulatory, and respiratory responses to surgical stimuli. Animals received a short acting opioid pain medication 3 times/day for 3days post-surgery and a long acting pain medication once/day for 48-72hrs. If it was determined by the veterinary staff that pain medication was needed after the prescribed regime, permission is given by the research staff for it to be prescribed to the animal as needed. After surgery the nonhuman primates were monitored for visible signs of infection or fever, mobility or swelling of the lower limbs, lameness, cold toes, plate limbs, as well as bleeding from surgical sites (anemia, reduced hematocrit); however, this was not observed during these studies, and no animals were terminated prior to study endpoint. At the implant study endpoint, to remove the implanted vascular grafts and analyze the results, the animals were euthanized according to the AVMA Guidelines on Euthanasia June 2007. For euthanasia, the animals were given ketamine 20 mg/kg followed by phenobarbitol (25 mg/kg) and exsanguination.
baboon. An ex vivo femoral arteriovenous shunt loop was established in the absence of anti-coagulant and anti-platelet therapies. EOC-seeded ePTFE grafts within custom chambers were connected to the shunt loop with blood flow controlled at 100 ml/min using a clamp downstream of the graft. This flow rate corresponds to an average of 10 dyn/cm 2 wall shear stress. Platelet deposition was measured for 1 hr using a gamma camera with 5 min exposure increments (static n526, steady n511, oscillatory n59). Fibrinogen accumulation was quantified at the study endpoint after complete decay (.10 half-lives) of the indium-111 (static n524, steady n59, oscillatory n59).
Implant studies
Aorto-iliac bypass ePTFE grafts were implanted bilaterally in juvenile male baboons, weighing 12-16 kg under anesthesia described above. After a midline incision, heparin (100 units/kg) was given and the aorta occluded with atraumatic microvascular clamps. Grafts were positioned between the distal aorta and common iliac artery, at the iliac bifurcation. Static (n57) or steady flowpretreated (n54) EOC-seeded samples were implanted contralaterally to an untreated ePTFE control sample. Grafts were seeded using autologous EOCs. Anastomoses were constructed (end-to-side) using continuous 7-0 polypropylene sutures. This procedure is similar to the standard surgical placement of such grafts in humans and produces progressive proliferative lesion formation at anastomotic sites. After 4wks, grafts were pressure fixed in 10% formalin and explanted. After overnight fixation in 10% formalin, the grafts were sectioned, dehydrated, embedded in paraffin, and stained with hematoxylin and eosin using standard histological procedures. The mid-point of the each anastomoses was analyzed for tissue ingrowth on the ePTFE grafts. The area of intimal hyperplasia was measured from the edge of the anastamosed artery to a 2 mm length into the graft using Image J. Trained viewers quantified these regions while blinded to which samples were controls or treated. The area of ingrowth was averaged across each 2 mm ingrowth section of the anastomosis. Intimal hyperplasia was only analyzed for patent anastomoses. While other groups have found differences between tissue ingrowth in the proximal and distal anatomoses [29, 30] , the historic data with our animal model for both bare and cell-seeded end-to-side vascular grafts have shown no difference between the two anastomoses [31] [32] [33] [34] . Therefore, data from this work were averaged across proximal and distal locations and analyzed to evaluate the hypothesis of endothelial cell flow preconditioning.
Correlations and linear regression model development
Single linear regression models were developed to correlate all in vitro data from each individual data point (FXa generation, APC generation, DNA quantity, CD39 gene expression, EPCR gene expression, TM gene expression, TF gene expression, TFPI gene expression, eNOS gene expression, ICAM gene expression, VCAM gene expression, and PECAM gene expression) to the parallel ex vivo data point (platelet accumulation at 60 min). The R 2 coefficient/value and p-value were used to examine the strength and significance of these single variable regressions. To create a predictive model of platelet accumulation, additional samples were added to challenge the data set and create a more robust model. In addition to the oscillatory flow, steady flow, and static samples described previously, a group of samples of EOC-coated grafts were stimulated with 100 U/ mL TNF (R&D Systems) for 4hrs prior to testing in vitro and ex vivo. This potent cytokine elicited a proinflammatory EOC phenotype, increasing the range of cell responses and potentially broadening the applicability of the developed regression model. When using gene data in the correlation analysis, values were converted to a linear scale using 2 -dCt . When a single factor correlation's p-value was less than 0.25, that factor was considered potentially important to develop the regression model. Factors that were strongly correlated to one another were not included in the same regression model. Models which resulted in strong correlations (R 2 .0.6) were tested using the in vitro control data collected parallel to implanted grafts to determine the applicability of the model to predict in vivo healing responses.
Statistical analysis
All data are presented as mean ¡ standard deviation. Sample numbers varied throughout this experiment, partially because static control samples were always run parallel to flow-or TNF-treated samples; however, n$3 for all treatment groups. Outlier analysis, defined as greater than 3 standard deviations away from the mean, was performed, but points were only removed when data collection indicated an error may have occurred. For example, samples were excluded if actin staining on parallel in vitro control samples indicated insufficient cell coverage on the graft. Unless otherwise stated, data were analyzed with a 1-way analysis of variance (ANOVA) to determine changes between treatment groups. Significance was indicated when p,0.05, and a Tukey's post hoc test was performed. A 2-way ANOVA was performed on the platelet accumulation data with factors of treatment and time. Data were checked for assumptions of ANOVA. Specifically, a Levene's test was performed to check for unequal variances, since sample sizes were not equal. Occasionally the data showed a slight skewedness (non-normality) in the distribution, and in these cases, a Box-Cox transformation was performed [35] . The same statistical analysis (ANOVA with a Tukey's post hoc) was run on the transformed data. Since there were no changes in the statistically-significant results, these transformations are not presented.
In the linear regression analysis, significance was determined using a main effects test for the overall regression and a 2-tailed t-test for the individual coefficients of the model. The standardized coefficients (beta) were determined in SPSS (IBM corp.) and indicate the scaled variables to compare the dominance of each of the variables compared to the others.
Results
Hemodynamic treatments altered the phenotype of EOCs
EOC phenotype in response to no flow (static), mean arterial (steady) flow, and disturbed (oscillatory) flow was characterized. In the absence of flow, the morphology of EOCs on ePTFE vascular grafts was typical of mature endothelial cells with elongation occurring in somewhat random orientation (Fig. 1A and  S1A Fig.) , but with the majority of the alignment seen in the circumferential direction (S2 Fig.) . Steady shear-treated EOCs (Fig. 1B and S1B Fig.) consistently showed elongation of the cells and alignment of the EOCs' actin cytoskeleton to the direction of fluid shear stress. Oscillatory shear-stimulated EOCs (Fig. 1C and  S1C Fig.) exhibited a rounded morphology. Despite these large morphological changes, cells were retained under all testing conditions and the DNA quantity (Fig. 1D) was unchanged between all treatment types. The hemodynamic conditions altered the expression of genes related to thrombin generation, platelet attachment, and inflammation relative to no-flow controls (Table 1) . Steady shear stress treatment caused a significant increase in eNOS and CD39 gene expression by the EOCs compared to the oscillatory shear stress treatment. Additionally, the hemodynamic conditions altered production of the two key components by which endothelial cells regulate thrombin generation, APC and FXa. Steady flow pretreatment of the EOCs significantly increased APC production ( Fig. 2A) compared to oscillatory shear stress pretreatment. Oscillatory shear-treated EOCs produced significantly more FXa (Fig. 2B) compared to the EOCs which remained under static conditions. Combined, these data show the prothrombotic phenotype elicited in the EOCs from oscillatory flow preconditioning.
Hemodynamic treatment of EOCs altered platelet and fibrin accumulation
To determine the effect of EOC phenotype on the antithrombotic properties of the endothelialized vascular grafts, flow preconditioned endothelialized grafts were placed in a well-established non-human primate model of vascular thrombosis. Platelet accumulation in the absence of anticoagulants was significantly higher in the oscillatory flow-stimulated sample compared to both the steady flow and static samples (Fig. 3A) . Steady flow conditioning of EOCcoated samples did not alter the amount of platelet accumulation compared to the static conditioned grafts. Fibrinogen incorporation was not significantly different between the three treatment groups (Fig. 3B) ; however, the average amount of fibrinogen in the oscillatory treatment samples was higher compared to static and steady flow samples.
Steady flow treatment did not alter vascular healing response on ePTFE grafts
To test whether steady flow treatment of EOC endothelialized vascular grafts would improve long term vascular responses, autologous EOC-coated vascular grafts with contralateral control ePTFE grafts (without cells) were implanted in a non-human primate, end-to-side aorto-illiac bypass model. All animals survived this study; however, in one implant, all four anastomoses (control and static cellseeded) were closed at explant. Two additional anastomoses from different animals both from cell-seeded distal sections without flow pretreatment were also not patent. Representative histology images from the distal anastomoses of each treatment group are shown in Fig. 4 . To account for the animal to animal Engineering an Endothelialized Vascular Graft variation, the amount of intimal hyperplasia on the endothelialized vascular grafts was normalized to the contralateral ePTFE control graft. The flow pre-treatment of the EOCs did trend toward lower intimal hyperplasia, although the difference was not statistically different (p50.162, Fig. 4D ).
Linear regression model results
To determine the potential for in vitro assessments of EOC function on vascular grafts to predict platelet accumulation, we developed a linear regression model. The linear regression analysis was performed on single in vitro variables for all individual data points against the corresponding total platelet accumulation at 60 min using the mechanically-and biochemically-modified EOC phenotypes ( Fig. 5 and S2 Table) . APC generation, FXa generation, DNA per surface area, and eNOS gene expression showed significant correlations (p,0.05); however, their R 2 values were still quite low, suggesting the need for multiple factors in Fig. 2 . In vitro functional data. Quantification of APC and FXa production by EOCs seeded onto ePTFE grafts and stimulated with steady fluid shear stress, oscillatory shear stress, or continued static culture for 24hrs after 24hrs of initial seeding. APC production per surface area (SA) was significantly higher in the steady flow treated sample when compared to the oscillatory flow treated sample (A) (*p50.05). FXa production per surface area was significantly higher in the oscillatory treated sample compared to the no flow control (B) (*p50.01). ANOVA, N$6.
doi:10.1371/journal.pone.0115163.g002
Engineering an Endothelialized Vascular Graft generating a regression model. Variables that resulted in highly not significant (p.0.5) correlations were ICAM, VCAM, and TF gene expression. Nineteen models, having between 2 and 4 variables, were tested based on the significance of the individual correlations when the TNF data were included. The R 2 values of these combined models ranged from 0.187 to 0.746 (S3 Table) . The highest R 2 value resulted from combining the factors FXa, eNOS, and CD39 ( Fig. 6A and S4 To determine the utility of the linear regression model predicting in vivo outcomes of implanted grafts, the model was applied to the data set from the in vitro grafts constructed in parallel to the implant grafts. From the regression Fig. 3 . Ex vivo platelet and fibrin data. EOC-seeded grafts in the ex vivo shunt loop had significantly more platelet deposition over 60 min when pretreated with oscillatory shear stress compared to either steady shear stress or no flow preconditioning (A) (*p50.01). Fibrinogen incorporation (B) also trended higher in oscillatory treated samples, but was not statistically different (p50.13). In samples that occluded before 60 min, platelet count at the time of occlusion was included through 60 min for the purposes of illustration. This occurred in three of the oscillatory samples. ANOVA, N$9.
doi:10.1371/journal.pone.0115163.g003
Engineering an Endothelialized Vascular Graft model, the platelet accumulation was predicted and compared to the in vivo outcome of anastomotic intimal hyperplasia. The FXa/eNOS/CD39 model correlated to intimal hyperplasia measurements at 4wks after graft implant with an R 2 value of 0.626 and a significance of 0.019 (Fig. 6B ).
Discussion
Endothelialization is expected to be a critical component for improving the patency of small diameter, artificial, vascular grafts. The past decade has seen a substantial increase in the interest in EOCs, and endothelial progenitor cells in general, for multiple therapeutic applications; however, considerable work is still needed to determine the applicability of these cells for vascular devices. The objectives of these studies were (1) to determine the ability of flow preconditioning to alter hemostatic regulation of EOCs in a clinically-relevant graft large animal model and (2) to correlate in vitro thrombogenic and inflammatory markers of EOCs with ex vivo and in vivo outcomes. Completing these objectives improves our understanding of EOCs, a clinically-feasible source for autologous endothelial cells, and suggests predictive metrics for vascular graft success in future implant designs. There is a considerable body of scientific work that has examined the response of mature endothelial cells to fluid shear stress, but only a handful of recent publications have explored the response of EOCs to these same stresses. Based on previous work with endothelial cells and EOCs [13] [14] [15] [36] [37] [38] [39] , it was expected that the application of steady flow would lead to a more anticoagulant and antiinflammatory EOC phenotype in vitro, reduced platelet accumulation ex vivo, and reduced intimal hyperplasia in vivo. When compared to oscillatory shear stress, this hypothesis was largely true. EOC gene expression of the anti-platelet molecules CD39 and eNOS were significantly increased after steady shear compared to oscillatory shear. EOCs produced significantly more APC in vitro when preconditioned with 10 dyn/cm 2 steady fluid shear stress compared to oscillatory, while oscillatory shear increased FXa production compared to static controls. Oscillatory flow preconditioning also increased platelet accumulation when compared to static or steady flow samples. These results corresponded well to previous work, which used the same conditioning on EOCs seeded on tissue culture plastic. Ankeny et al. [14] measured increases in EOC gene expression of thromboprotective genes (including eNOS and CD39) but saw no change in Engineering an Endothelialized Vascular Graft inflammatory, TF, or TFPI genes for oscillatory stimulation compared to steady shear. Oscillatory flow consistently produced a procoagulant phenotype in the EOCs, confirming EOC sensitivity to disturbed hemodynamic conditions. An unexpected observation was the lack of differences between EOCs under steady fluid shear stress compared to static conditions. There were no significant differences between steady flow and static preconditioning for APC or FXa generation. The platelet accumulation on these samples was nearly identical over 60 min, and no differences were seen in fibrinogen incorporation. Ahmann et al. [13] observed no change in ICAM or VCAM gene expression between static and steady shear stress, but most previous work observed changes in thrombosis markers with steady flow. Previous work on EOCs demonstrated an increase in TM protein [36] and gene expression [36, 37, 40] , an increase in TFPI gene expression [36] , and an increase in APC production [36, 40] with steady shear stress compared to static. NO production [13] , eNOS gene expression Engineering an Endothelialized Vascular Graft [13, 15, 36, 37, 39] , and eNOS protein production [15] by EOCs have all been observed to increase under steady shear stress compared to no flow conditions. Platelet binding also decreased with steady flow preconditioning of EOCs compared to static samples; however, both these groups used heparized blood over a shorter period of time than the work presented here [13, 39] . The TF results due to steady flow preconditioning on EOCs were not consistent with one group observing a decrease in TF gene expression [15] , another observing an increase in TF gene expression and protein [40] , and a third observing no significant change in TF gene expression [38] ; however, as with mature endothelial cells, the application of steady fluid shear stress has generally led to a more anticoagulant phenotype in previous studies of EOCs. While the differences seen with this work could be attributed to minor differences in experimental design such as species, matrix coating, or magnitude of the fluid stress, such profound differences suggest a more fundamental change has occurred.
The largest difference between the previous work and the work presented here is likely the material on which the cells were adhered and the way this material impacted cell morphology, altering the static EOC phenotype. Most of the previous work comparing steady shear to static preconditioning was completed on flat surfaces of matrix-coated tissue culture plastic or glass [14, 15, 36, 37] . The collagen-coated ePTFE grafts used here have a distinct topography with a fiber structure that encourages elongation of the EOCs in the circumferential direction. While EOCs seeded on a truly flat surface will exhibit a primarily cobblestone morphology in the absence of flow, the EOCs in this study were frequently observed to be elongated on the ePTFE without fluid shear stimulation. The significance of this morphological change is the corresponding phenotypic change that accompanies endothelial cell elongation. As reviewed elsewhere [41] , endothelial cells that are compelled into an elongated morphology without flow exhibit many similarities to endothelial cells elongated with steady fluid shear stress. Multiple researchers have shown through a direct comparison of endothelial cells elongated with flow or with cell patterning that the extent of elongation and the orientation of the cytoskeleton are very similar between flow and patterned endothelial cells. The transcription factor krüppel-like factor 2, which was previously thought to be shear stress-dependent, has also been shown to increase in patterned endothelial cells, illustrating the importance of elongation on endothelial cell phenotype [42] . Elongation due to either patterning or flow decreased primary endothelial cell expression of both TFPI and von Willebrand factor genes [43] , which likely contributes to the similarities seen here in FXa production and platelet accumulation between static and steady flow conditioned EOC samples. Additionally, previous work showed that both methods of elongation lead to a decrease in the expression of inflammation markers such as VCAM and E-selectin [42] , offering a potential explanation to the lack of statistical difference in intimal hyperplasia between static and steady shear preconditioned EOC grafts when implanted in an aorto-illiac bypass graft for 1mth. The ePTFE topography contributed to the elongation of the EOCs and the resulting elongated morphology may provide a thromboprotective phenotype similar to that previously observed with steady fluid shear stress. Future work toward altering EOC phenotype through either fluid shear stress or physical cell alignment will be important toward improving antithrombotic function.
In this study, the elongation imparted on the EOCs though the ePTFE ultrastructure resulted in equivalent EOC phenotype for the no flow and steady flow preconditioned cells. However, there was a trend that steady shear stress decreased intimal hyperplasia, when normalized to the contralateral acellular control graft. Additional research should further examine the potential benefit of flow preconditioning of EOC-seeded grafts. Work that seeks to improve biological integration of vascular grafts by harnessing the regulatory function of the native endothelium should be pursued to permit small diameter graft patency. Future work should also identify methods to improve the durability of an intact endothelial layer on graft materials.
Much hope has been placed in the potential to tissue engineer a vascular graft to improve clinical outcomes at small diameters, but constructs that have been created and characterized in vitro and subsequently tested in vivo with small animal models have yet to translate into a viable graft replacement. For example, work by Stroncek et al. [29] . observed no significant change in intimal hyperplasia when EOCs were transfected with TM compared to unmodified EOCs even though their previous work saw a dramatic increase in APC production with the transfection in vitro [44] . While their work did support EOC endothelialization of vascular grafts compared to bare ePTFE grafts, it also motivates a better understanding of the cell phenotype necessary for improving in vivo outcomes. Determining the in vitro properties that correlate to positive in vivo outcomes is essential for the development of successful bioengineered grafts. Combining all of the in vitro assessments performed here in parallel to ex vivo assessments allowed for a thorough examination of the extent to which these factors directly correlate to platelet accumulation. The second hypothesis of this work was that in vitro measures of the EOC functions would correlate with ex vivo platelet accumulation. Individually, a variety of in vitro metrics of EOC-seeded vascular grafts significantly correlated to platelet accumulation: APC generation, FXa generation, DNA per surface area, and eNOS gene expression. However, none of these individual correlations was very strong. This was not surprising given the multiple regulatory pathways of coagulation, further motivating the combination of factors in a regression model. A multifactor linear regression analysis determined that a model combining FXa generation, eNOS gene expression, and CD39 gene expression correlated well to platelet data. Interestingly, FXa generation was consistently the most predominant of these factors, as was indicated in the statistical analysis by larger beta values, larger t-values, and lower p-values, but expression of genes relating to FXa generation, TF and TFPI, were not significant factors. This suggests the strength of this functional assay compared to gene expression data, which does not reflect post-translational regulation. It was surprising that many of the variables did not significantly correlate to the platelet accumulation, further emphasizing the importance of determining predictive in vitro metrics. While many researchers test inflammatory markers, most often using gene expression, the lack of correlation with ICAM and VCAM observed here suggests that inflammation-induced gene expression data may not translate well into clinical performance. This is the first work of this type, which attempts to determine predictive metrics for in vivo vascular graft performance from in vitro endothelial markers. The model was created from ex vivo platelet data; however, the model of predicted platelet attachment when applied to in vitro data from parallel implant samples correlated strongly to intimal hyperplasia. This is a very encouraging result, although not unexpected given the ability of platelets to release growth factors like TGF and PDGF, which encourage smooth muscle cell migration and proliferation-critical to the tissue ingrowth characteristic of intimal hyperplasia [45] [46] [47] . The strength of this correlation is intriguing and suggests the true potential of these specific in vitro tests to predict in vivo performance. However, more work is needed to confirm this potential. The study of the ability of EOCs to alter vascular responses in vivo is currently being studied with sheep EOCs on tissue engineered grafts [12, 48] . Future work should examine the applicability of our regression model to other tissue engineered graft conditions, including other sources of endothelial cells, graft surfaces, or preconditioning methods. Genetic manipulations to increase single factors within a thromboprotective and thromboprone EC phenotype could identify key regulators of platelet attachment and tissue ingrowth. Having strong predictors for thrombogenicity and ultimately in vivo remodeling could drastically decrease the resources necessary to translate a tissue engineered graft into a successful clinical product.
This work presents comprehensive in vitro, ex vivo, and in vivo results on flow preconditioning of EOCs on vascular grafts using steady and oscillatory flow conditions. Additionally, this work addresses an important gap in knowledge by beginning to determine the predictive factors important in graft implant success. Gaining a better understanding of these factors should improve future work on vascular grafts for the long-term, clinical improvement of small diameter vascular graft products. 
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